Primaquine
Active ingredient: Primaquine Phosphate
In short: Primaquine phosphate tablets are indicated for the radical cure (prevention of relapse) of vivax malaria.
What is Primaquine used for?
Primaquine phosphate tablets are indicated for the radical cure (prevention of relapse) of vivax malaria.
âš Boxed warning (FDA's strongest warning)
Hemolytic reactions (moderate to severe) may occur in individuals with G6PD deficiency and in individuals with a family or personal history of favism. Areas of high prevalence of G6PD deficiency are Africa, Southern Europe, Mediterranean region, Middle East, South-East Asia, and Oceania. People from these regions have a greater tendency to develop hemolytic anemia due to a congenital deficiency of erythrocytic G6PD while receiving primaquine and related drugs.
Due to the risk of hemolytic anemia in patients with G6PD deficiency, G6PD testing must be performed before using primaquine. Before initiating treatment, obtain baseline hemoglobin and hematocrit. In case of severe anemia, postpone the G6PD test and decision on treatment with primaquine until recovery.
Due to the limitations of G6PD tests, physicians need to be aware of residual risk of hemolysis and adequate medical support and follow-up to manage hemolytic risk should be available. This is of particular importance in individuals with a personal or family history of hemolytic anemia.
Patients with G6PD Deficiency
Primaquine phosphate tablets are contraindicated in patients with severe G6PD deficiency .
In case of mild to moderate G6PD deficiency, a decision to prescribe primaquine must be based on an assessment of the risks and benefits of using primaquine. If primaquine administration is considered, baseline hematocrit and hemoglobin must be checked before treatment and close hematological monitoring (e.g., at day 3 and 8) is required. Adequate medical support to manage hemolytic risk should be available. …
Primaquine dosage
Primaquine phosphate tablets are recommended only for the radical cure of vivax malaria, the prevention of relapse in vivax malaria, or following the termination of chloroquine phosphate suppressive therapy in an area where vivax malaria is endemic. Patients suffering from an attack of vivax malaria or having parasitized red blood cells should receive a course of chloroquine phosphate, which quickly destroys the erythrocytic parasites and terminates the paroxysm. Primaquine phosphate tablets should be administered concurrently to eradicate the exoerythrocytic parasites in adults at a dosage of 1 tablet (equivalent to 15 mg base) daily for 14 days.
Primaquine phosphate tablets can be taken with or without food. Administration of primaquine phosphate tablets with food may reduce the incidence of gastrointestinal symptoms.
Warnings & precautions
Do not take this medicine if: Known hypersensitivity reactions to primaquine phosphate, other 8-Âaminoquinolones, or to any component in primaquine phosphate tablets.
Severe glucose-6-phosphate dehydrogenase (G6PD) deficiency .
Pregnant women .
Breastfeeding by a lactating woman when the infant is found to be G6PD deficient or if G6PD status is unknown .
Because quinacrine hydrochloride appears to potentiate the toxicity of antimalarial compounds which are structurally related to primaquine, the use of quinacrine in patients receiving primaquine phosphate tablets is contraindicated. Similarly, primaquine phosphate tablets should not be administered to patients who have received quinacrine recently, as toxicity is increased.
Primaquine may cause a transient increase in methemoglobin levels up to 10% in patients without risk factors . Methemoglobinemia may be severe in patients who are deficient in nicotinamide adenine dinucleotide (NADH), methemoglobin reductase or treated with methemoglobinemia-inducing drugs such as dapsone or sulfonamide, . Monitor methemoglobin levels closely in these cases.
Advise all patients to seek immediate medical attention if signs of methemoglobinemia occur such as bluish lips or nails.
Leukopenia
Primaquine may cause leukopenia in patients with established granulocytopenia, such as rheumatoid arthritis and lupus erythematosus. Avoid concurrent administration of bone-marrow depressants. Discontinue the use of primaquine promptly if there is a sudden decrease in leukocyte count.
Due to potential for QT interval prolongation, monitor ECG when using primaquine in patients with cardiac disease, long QT syndrome, a history of ventricular arrhythmias, uncorrected hypokalemia and/or hypomagnesemia, or bradycardia (<50 bpm), and during concomitant administration with QT interval prolonging agents . …
Primaquine side effects
To report SUSPECTED ADVERSE REACTIONS, please call Ingenus Pharmaceuticals, LLC at 1-877-748-1970 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Gastrointestinal: Nausea, vomiting, epigastric distress, abdominal cramps.
Hematologic: Leukopenia, hemolytic anemia, decreased hemoglobin, methemoglobinemia.
Hemolytic anemia occurs commonly in patients with G6PD deficiency and may be severe or fatal in patients with severe G6PD deficiency .
Methemoglobin levels are usually <10%, but methemoglobinemia may be severe in nicotinamide adenine dinucleotide (NADH) methemoglobin reductase deficient individuals or in patients with other risk factors .
Leukopenia was observed in patients with rheumatoid arthritis or lupus erythematosus .
Cardiac: Cardiac arrhythmia and QT interval prolongation .
Nervous System: Dizziness.
Skin and Soft Tissue: Rash, pruritus.
About this medicine
Primaquine phosphate is 8-[(4-amino-1-methylbutyl) amino]-6-methoxyquinoline phosphate, a synthetic compound with potent antimalarial activity. The molecular formula of primaquine phosphate is C15H21N3O·2H3PO4 and its molecular weight is 455.34. The structural formula of primaquine phosphate is:
Figure 1: Primaquine phosphate structure.
Each primaquine phosphate tablet, USP contains 26.3 mg of primaquine phosphate (equivalent to 15 mg of primaquine base). The dosage is customarily expressed in terms of the base.
Inactive Ingredients: Hypromellose, Lactose Monohydrate, Magnesium Stearate, Microcrystalline Cellulose, Triacetin, Pregelatinized Starch, FD&C Yellow#6/Sunset Yellow FCF Aluminum Lake, Talc, Titanium Dioxide.
How it works: Mechanism of Action Primaquine phosphate is an 8-aminoquinoline antimalarial drug. The mechanism of action has not been fully established. The major assumptions are an inhibition of the mitochondrial system of dormant parasites, and an oxidative stress generated through reactive metabolites in infected cells.
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 09531382-2e06-4164-a7e1-169a1488788a. Read the full official label on DailyMed.